Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02525263 · ClinicalTrials.gov registry record · Phase 2
Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)
A Phase 2 study, sponsored by Prokidney.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02525263 is a Phase 2 study that was terminated before completion, run by Prokidney. The registered enrollment target is 1 participants.
The verdict
NCT02525263, a Phase 2 study, was terminated before completion, sponsored by Prokidney.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001). NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. All enrolled subjects will be treated with up to two injections of NKA at least 6 months apart.
Interventions
- BIOLOGICAL Neo-Kidney Augment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02525263
The ClinicalTrials.gov registry entry for NCT02525263 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prokidney, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neo-Kidney Augment is the first listed.
NCT02525263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02525263 about?
NCT02525263 is a clinical study titled "Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)". A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001). NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. All enrolled subjects will b...
What is the current status of trial NCT02525263?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-07. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02525263?
The interventions under investigation include: Neo-Kidney Augment (BIOLOGICAL).
Who is sponsoring clinical trial NCT02525263?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.